IA
VYNE icon

IFP Advisors’s VYNE Therapeutics VYNE Stock Holding History

IFP Advisors’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-31
Closed -$2.45K – 3262
2021
Q1 		$4K Buy
31
+15
+94% +$2.17K ﹤0.01% 2505
2020
Q4 		$2K Buy
16
+14
+700% +$1.76K ﹤0.01% 2673
2020
Q3 		$0 Hold
2
– – ﹤0.01% 3017
2020
Q2 		$0 Buy
+2
New +$271 ﹤0.01% 2969

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

IFP Advisors's VYNE Position: Q2 2021 in Review

IFP Advisors sold out of VYNE Therapeutics (VYNE) in Q2 2021, closing a stake of 31 shares — an estimated $2.45K sold.

IFP Advisors first reported a position in VYNE in Q2 2020 and held it in 4 quarters. The position peaked at $4K in Q1 2021. 72 funds tracked by Wall St. Rank hold VYNE as of Q2 2021.

  • IFP Advisors reported no remaining VYNE Therapeutics position as of Q2 2021 after selling out during the quarter.
  • IFP Advisors sold 31 VYNE Therapeutics shares in Q2 2021, an estimated $2.45K.
  • IFP Advisors first reported a position in VYNE Therapeutics in Q2 2020 and held it in 4 quarters.
  • IFP Advisors's VYNE Therapeutics position peaked at $4K in Q1 2021.
  • 72 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2021.

Based on IFP Advisors's 13F filing for Q2 2021, filed 13 Jul 2021.